A Phase 3 interventional study of Benralizumab and Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 431 sites in 24 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-21.
Sponsored by AstraZeneca · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 20 in phase 3, and was the 11th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,133 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 11th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2014, is one of 121 in phase 3, and was the 193rd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
After a minimum of 1200 patients have been enrolled in this study, subsequent patients (up to a maximum of 2200 total for the study), who complete a minimum of 16 weeks, and no more than 40 weeks, in this study, will be given the option to transition to an open-label safety extension study, Study D3250C00037 (MELTEMI).
Adolescent patients, patients from Japan and South Korea, and any patient who chooses not to enter Study D3250C00037 will remain in this study through IPD or EOT and FU.
At the time of the first interim analysis in Japanese patients, the study regimen for all patients will become unblinded to AstraZeneca for data analysis purposes. Study conduct and blinding at the site and patient level will remain unchanged.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Biological: Benralizumab
Benralizumab administered subcutaneously
Biological: Benralizumab
Benralizumab administered subcutaneously
Benralizumab administered subcutaneously
Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in hematologic lab parameter of Basophils.
Time frame: Week 56
Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Basophils.
Time frame: Week 108
Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in hematologic lab parameter of Leukocytes.
Time frame: Week 56
Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Leukocytes.
Time frame: Week 108
Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in hematologic lab parameter of Lymphocytes.
Time frame: Week 56
Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Lymphocytes.
Time frame: Week 108
Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in hematologic lab parameter of Neutrophils.
Time frame: Week 56
Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Neutrophils.
Time frame: Week 108
Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in hematologic lab parameter of Eosinophils.
Time frame: Week 56
Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Eosinophils.
Time frame: Week 108
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in chemistry tests ALT.
Time frame: Week 56
Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of ALT.
Time frame: Week 108
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in chemistry tests AST.
Time frame: Week 56
Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of AST.
Time frame: Week 108
Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients
Change from baseline in chemistry test Bilirubin.
Time frame: Week 56
Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
Change from baseline in hematologic lab parameter of Bilirubin.
Time frame: Week 108
Number of Overall Patients With Asthma Exacerbations During Study Period
Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
Time frame: From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose)
Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)
Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
Time frame: From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose)
Change From Baseline in Pre-bronchodilator FEV1 (L)
Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).
Time frame: Week 56
Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)
Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).
Time frame: Week 108
Change From Baseline in Post-bronchodilator FEV1 (L)
Change from baseline to Week 56 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).
Time frame: Week 56
Change From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)
Change from baseline to Week 108 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).
Time frame: Week 108
Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients
Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.
Time frame: Week 56
Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)
Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.
Time frame: Week 108
Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)
Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.
Time frame: Week 56
Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)
Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.
Time frame: Week 108
Change of Blood Eosinophil Levels' Measurement in Overall Patients
Change from baseline to Week 56 in Blood eosinophils
Time frame: Week 56
Change of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).
Change from baseline to Week 108 in Blood eosinophils.
Time frame: Week 108
Change From Baseline in EQ-5D-5L Visual Analog Scale
The questionnaire included a visual analog scale (VAS) score, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.
Time frame: Week 56
Change From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)
The questionnaire included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.
Time frame: Week 108
Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.
Time frame: Week 68
Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.
Time frame: Week 108
Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)
The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.
Time frame: Week 56
Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)
The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.
Time frame: Week 108
Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Week 68
Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Week 108
Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period
Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma
Time frame: From week 0 to week 68 in study treatment period and through the follow up period (16 weeks from day of last dose)
Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)
Hospitalizations, ED visits, urgent care visits and all other outpatient visits due to asthma
Time frame: Baseline and Week 108
Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study
Endpoint: Pharmacokinetic (PK) parameters
Time frame: Week 0 and Week 56
Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)
Endpoint: Pharmacokinetic (PK) parameters
Time frame: Baseline and Week 108
Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study
Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study
Time frame: From week 0 to week 56 in study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period
Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)
Assessments for the presence of ADA and nAb throughout study
Time frame: From week 0 to week 108 study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period
2133 patients entered BORA. 10 were excluded due to a GCP breach. Of remaining 2123 patients, 1926 entered from SIROCCO/CALIMA and 197 from ZONDA. 2 patients were not treated, and a total of 447 patients (348 SIROCCO/CALIMA and 99 ZONDA) were later enrolled into MELTEMI without completing the follow-up in BORA, so not in the main analyses.
| Milestone | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Started | 953 | 973 | 100 | 97 |
| Treated | 953 | 971 | 100 | 97 |
| Adolescents only | 25 | 61 | 0 | 0 |
| Completed | 911 | 924 | 92 | 92 |
| Not completed | 42 | 49 | 8 | 5 |
| Withdrew: Eg. not made to the visit | 7 | 4 | 0 | 1 |
| Withdrew: Study specific discount. criteria | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 20 | 7 | 1 |
| Withdrew: Lost to follow-up | 5 | 12 | 1 | 2 |
| Withdrew: Death | 5 | 4 | 0 | 1 |
| Withdrew: Adverse event | 3 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 | 0 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 2 | 0 | 0 |
Change from baseline in hematologic lab parameter of Basophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | -0.005 ± 0.0223 | -0.005 ± 0.0239 | -0.007 ± 0.0283 | -0.005 ± 0.0244 |
Change from baseline in hematologic lab parameter of Basophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.006 ± 0.0145 | 0.001 ± 0.0208 |
Change from baseline in hematologic lab parameter of Leukocytes.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | -0.344 ± 2.0412 | -0.128 ± 1.8614 | -0.808 ± 1.8177 | -0.507 ± 3.3612 |
Change from baseline in hematologic lab parameter of Leukocytes.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.487 ± 1.7289 | -0.079 ± 1.8432 |
Change from baseline in hematologic lab parameter of Lymphocytes.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | -0.032 ± 0.6242 | 0.003 ± 0.5402 | -0.093 ± 0.6403 | 0.007 ± 0.6864 |
Change from baseline in hematologic lab parameter of Lymphocytes.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.180 ± 0.6946 | -0.070 ± 0.6671 |
Change from baseline in hematologic lab parameter of Neutrophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients | -0.171 ± 1.8746 | 0.013 ± 1.7024 | -0.501 ± 1.7096 | -0.368 ± 3.2057 |
Change from baseline in hematologic lab parameter of Neutrophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.451 ± 1.7645 | 0.242 ± 1.8469 |
Change from baseline in hematologic lab parameter of Eosinophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients | -0.1220 ± 0.30599 | -0.1271 ± 0.26161 | -0.1451 ± 0.30766 | -0.1664 ± 0.35139 |
Change from baseline in hematologic lab parameter of Eosinophils.
| 10^9 cells/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.1294 ± 0.27973 | -0.1838 ± 0.3381 |
Change from baseline in chemistry tests ALT.
| ukat/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients | -0.007 ± 0.2102 | 0.017 ± 0.4651 | -0.064 ± 0.3547 | -0.023 ± 0.1940 |
Change from baseline in hematologic lab parameter of ALT.
| ukat/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | 0.048 ± 0.2195 | 0.034 ± 0.2312 |
Change from baseline in chemistry tests AST.
| ukat/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients | -0.005 ± 0.1431 | 0.004 ± 0.3303 | -0.027 ± 0.2291 | -0.026 ± 0.1178 |
Change from baseline in hematologic lab parameter of AST.
| ukat/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | -0.006 ± 0.1196 | -0.013 ± 0.1297 |
Change from baseline in chemistry test Bilirubin.
| umol/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients | 0.187 ± 3.6261 | 0.391 ± 3.9945 | 0.146 ± 2.8094 | 0.279 ± 3.8765 |
Change from baseline in hematologic lab parameter of Bilirubin.
| umol/L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | 2.221 ± 8.3453 | 0.202 ± 3.6575 |
Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4 | ZONDA - Benralizumab 30 mg q.4 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8 | ZONDA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL — Number of exacerbation | 99 | 60 | 159 | 104 | 66 | 170 | — | — | — | — | — | — |
| Sirocco/Calima patients with eos<300/μL — Number of exacerbation | 69 | 44 | 113 | 65 | 32 | 97 | — | — | — | — | — | — |
| Zonda Patients with asthma exacerbations — Number of exacerbation | — | — | — | — | — | — | 12 | 5 | 17 | 13 | 11 | 24 |
Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL — Number of exacerbation | 2 | 6 | 8 | 3 | 5 | 8 |
| Sirocco/Calima patients with eos<300/μL — Number of exacerbation | 0 | 0 | 0 | 5 | 6 | 11 |
Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).
| L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4 | ZONDA - Benralizumab 30 mg q.4 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8 | ZONDA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | -0.006 ± 0.295 | 0.131 ± 0.422 | 0.038 ± 0.346 | 0.019 ± 0.317 | 0.081 ± 0.419 | 0.040 ± 0.356 | — | — | — | — | — | — |
| Sirocco/Calima patients with eos<300/μL | -0.021 ± 0.376 | -0.011 ± 0.280 | -0.017 ± 0.345 | -0.015 ± 0.293 | 0.030 ± 0.350 | -0.001 ± 0.312 | — | — | — | — | — | — |
| Number of Zonda Patients | — | — | — | — | — | — | 0.013 ± 0.354 | 0.167 ± 0.533 | 0.057 ± 0.412 | -0.093 ± 0.280 | 0.138 ± 0.329 | -0.012 ± 0.314 |
Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).
| L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 0.205 ± 0.289 | -0.189 ± 0.354 | -0.020 ± 0.375 | 0.578 ± 0.608 | 0.413 ± 0.375 | 0.496 ± 0.502 |
| Sirocco/Calima patients with eos<300/μL | 0.325 ± 0.431 | 1.140 ± NA | 0.597 ± 0.561 | 0.047 ± 0.340 | 0.240 ± 0.519 | 0.147 ± 0.444 |
Change from baseline to Week 56 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).
| L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | -0.066 ± 0.280 | 0.089 ± 0.455 | -0.015 ± 0.354 | -0.029 ± 0.281 | 0.045 ± 0.401 | -0.004 ± 0.329 |
| Sirocco/Calima patients with eos<300/μL | -0.058 ± 0.379 | -0.024 ± 0.289 | -0.046 ± 0.350 | -0.043 ± 0.273 | 0.049 ± 0.394 | -0.015 ± 0.316 |
Change from baseline to Week 108 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).
| L | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | -0.062 ± 0.537 | -0.305 ± 0.394 | -0.201 ± 0.458 | 0.603 ± 0.749 | 0.279 ± 0.659 | 0.448 ± 0.712 |
| Sirocco/Calima patients with eos<300/μL | 0.375 ± 0.474 | 0.880 ± NA | 0.543 ± 0.444 | -0.006 ± 0.327 | 0.218 ± 0.536 | 0.111 ± 0.454 |
Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4 | ZONDA - Benralizumab 30 mg q.4 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8 | ZONDA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | -0.04 ± 0.83 | -0.20 ± 1.04 | -0.09 ± 0.91 | -0.06 ± 0.82 | -0.25 ± 1.06 | -0.12 ± 0.91 | — | — | — | — | — | — |
| Sirocco/Calima patients with eos<300/μL | -0.16 ± 0.90 | -0.12 ± 0.80 | -0.15 ± 0.86 | -0.10 ± 0.83 | -0.09 ± 1.06 | -0.10 ± 0.90 | — | — | — | — | — | — |
| Number of Zonda Patients | — | — | — | — | — | — | -0.05 ± 0.89 | -0.61 ± 0.74 | -0.21 ± 0.87 | 0.15 ± 1.02 | -0.43 ± 1.00 | -0.05 ± 1.04 |
Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 0.26 ± 0.53 | 0.06 ± 0.49 | 0.16 ± 0.50 | -0.14 ± 0.51 | -0.10 ± 1.38 | -0.12 ± 1.02 |
| Sirocco/Calima patients with eos<300/μL | -0.50 ± 0.24 | -1.83 ± NA | 0.94 ± 0.79 | -0.21 ± 0.78 | -0.21 ± 0.77 | -0.21 ± 0.76 |
Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4 | ZONDA - Benralizumab 30 mg q.4 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8 | ZONDA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 0.02 ± 0.80 | 0.21 ± 0.98 | 0.08 ± 0.87 | 0.08 ± 0.91 | 0.26 ± 1.00 | 0.15 ± 0.94 | — | — | — | — | — | — |
| Sirocco/Calima patients with eos<300/μL | 0.11 ± 0.84 | 0.03 ± 0.89 | 0.09 ± 0.85 | 0.15 ± 0.90 | 0.02 ± 1.06 | 0.11 ± 0.95 | — | — | — | — | — | — |
| Number of Zonda Patients | — | — | — | — | — | — | 0.13 ± 0.93 | 0.43 ± 0.91 | 0.22 ± 0.92 | -0.04 ± 0.94 | 0.40 ± 1.03 | 0.11 ± 0.98 |
Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 0.60 ± 1.22 | -0.11 ± 0.21 | 0.25 ± 0.92 | 0.52 ± 0.37 | 0.06 ± 0.59 | 0.29 ± 0.54 |
| Sirocco/Calima patients with eos<300/μL | 0.64 ± 0.55 | 1.53 ± NA | 0.94 ± 0.65 | 0.58 ± 1.01 | 0.27 ± 0.77 | 0.42 ± 0.89 |
Change from baseline to Week 56 in Blood eosinophils
| cell/uL | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4 | ZONDA - Benralizumab 30 mg q.4 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8 | ZONDA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 4.9 ± 177.42 | -449.6 ± 360.6 | -148.6 ± 332.91 | -10.1 ± 134.7 | -422.5 ± 330.01 | -154.1 ± 297.34 | — | — | — | — | — | — |
| Sirocco/Calima patients with eos<300/μL | 15.7 ± 87.04 | -222.1 ± 325.03 | -68.4 ± 234.40 | -2.9 ± 59.11 | -217.4 ± 198.56 | -74.7 ± 160.29 | — | — | — | — | — | — |
| Number of Zonda Patients | — | — | — | — | — | — | 2.5 ± 69.85 | -520.9 ± 360.79 | -145.1 ± 307.66 | -17.0 ± 107.48 | -435.3 ± 468.64 | -166.4 ± 351.39 |
Change from baseline to Week 108 in Blood eosinophils.
| cell/uL | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 78.3 ± 192.19 | -356.7 ± 215.47 | -139.2 ± 299.16 | -163.6 ± 502.76 | -332.9 ± 349.89 | -229.4 ± 446.21 |
| Sirocco/Calima patients with eos<300/μL | 160.0 ± NA | -150.0 ± NA | 5.0 ± 219.20 | -2.0 ± 9.19 | -204.4 ± 152.32 | -97.9 ± 145.40 |
The questionnaire included a visual analog scale (VAS) score, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 6.08 ± 15.68 | 6.02 ± 17.68 | — | — |
| Sirocco/Calima patients with eos<300/μL | 4.38 ± 14.99 | 6.69 ± 15.96 | — | — |
| Number of Zonda Patients | — | — | 5.00 ± 10.35 | 1.36 ± 13.58 |
The questionnaire included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.
| Score on a scale | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 5.43 ± 9.73 | 6.63 ± 15.53 | 6.07 ± 12.71 | 11.54 ± 26.95 | 9.83 ± 13.87 | 10.72 ± 21.26 |
| Sirocco/Calima patients with eos<300/μL | 22.00 ± 12.73 | -4.00 ± NA | 13.33 ± 17.50 | 10.18 ± 32.69 | 5.08 ± 10.45 | 7.52 ± 23.39 |
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.
| percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 68 | 23.3 ± 26.18 | 21.0 ± 25.54 | — | — |
| Sirocco/Calima patients with eos<300/μL-wk 68 | 32.7 ± 27.55 | 25.8 ± 24.05 | — | — |
| Zonda Patients-wk 68 | — | — | 18.9 ± 24.94 | 21.0 ± 27.13 |
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.
| Percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 108 | 0.0 ± 0.00 | 10.0 ± NA | 3 ± 3.3 | 20.0 ± NA | 10.0 ± NA | 15.0 ± 7.07 |
| Sirocco/Calima patients with eos<300/μL-wk-108 | — | — | — | 0.0 ± 0.00 | 13.3 ± 5.77 | 8.0 ± 8.37 |
The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.
| Percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 56 | 3.8 ± 7.44 | 15.2 ± 20.69 | — | — |
| Sirocco/Calima patients with eos<300/μL-wk 56 | 5.0 ± 7.07 | 17.1 ± 20.06 | — | — |
The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.
| Percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 108 | 4.9 ± 6.82 | 15.2 ± 17.55 | 9.5 ± 12.98 | 5.4 ± 8.32 | 18.6 ± 27.94 | 12.3 ± 21.62 |
| Sirocco/Calima patients with eos<300/μL-wk-108 | 21.5 ± 30.41 | — | 21.5 ± 30.41 | 12.5 ± 18.10 | 10.6 ± 11.68 | 11.5 ± 14.66 |
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
| percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 68 | 26.6 ± 26.14 | 24.4 ± 25.26 | — | — |
| Sirocco/Calima patients with eos<300/μL-wk 68 | 33.6 ± 26.55 | 32.7 ± 26.58 | — | — |
| Zonda Patients-wk 68 | — | — | 28.4 ± 27.85 | 39.0 ± 34.36 |
The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
| Percentage | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL-wk 108 | 7.1 ± 11.13 | 5.0 ± 9.26 | 6.0 ± 9.86 | 5.4 ± 8.77 | 19.2 ± 24.31 | 12.3 ± 19.25 |
| Sirocco/Calima patients with eos<300/μL-wk-108 | 10.0 ± 14.14 | 20.0 ± NA | 13.3 ± 11.55 | 14.2 ± 18.81 | 11.5 ± 10.68 | 12.8 ± 14.87 |
Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 193 | 198 | — | — |
| Sirocco/Calima patients with eos<300/μL | 118 | 102 | — | — |
| Number of Zonda Patients | — | — | 20 | 25 |
Hospitalizations, ED visits, urgent care visits and all other outpatient visits due to asthma
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|---|---|
| Sirocco/Calima patients with eos>=300/μL | 2 | 5 | 7 | 7 | 7 | 14 |
| Sirocco/Calima patients with eos<300/μL | 0 | 1 | 1 | 7 | 5 | 12 |
Endpoint: Pharmacokinetic (PK) parameters
| ng/mL | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo | ZONDA - Benra 30 mg q.4 Weeks - Pre Benra q.4 | ZONDA - Benra 30 mg q.4 wk - Predecessor Placebo | ZONDA - Benra 30 mg q.8 Weeks - Pre Benra q.8 | ZONDA - Benra 30 mg q.8 wk - Predecessor Placebo |
|---|---|---|---|---|---|---|---|---|
| Baseline | 714.25 (624.48 to 816.93) | NA (NA to NA) | 142.92 (124.08 to 164.63) | NA (NA to NA) | 964.21 (589.87 to 1576.11) | NA (NA to NA) | 692.91 (428.49 to 1120.50) | NA (NA to NA) |
| Week 56 | 930.04 (825.89 to 1047.33) | 865.93 (721.50 to 1039.27) | 173.95 (151.81 to 199.33) | 162.03 (132.31 to 195.43) | 823.62 (476.98 to 1422.17) | 1160.58 (833.77 to 1615.49) | 247.26 (165.87 to 368.57) | 139.35 (61.90 to 313.70) |
Endpoint: Pharmacokinetic (PK) parameters
| ng/mL | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4 | SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor Placebo | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8 | SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo |
|---|---|---|---|---|
| Baseline | 725.55 (231.38 to 2275.13) | NA (NA to NA) | 218.53 (126.53 to 377.42) | NA (NA to NA) |
| Week 108 | 383.73 (30.90 to 4764.79) | 853.51 (260.26 to 2799.03) | 436.85 (185.36 to 1029.59) | 524.39 (287.72 to 955.74) |
Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Positive at any visit | 80 | 93 | 4 | 8 |
| Base- and Post-baseline Positive | 23 | 41 | 2 | 4 |
| Newly Persistently Positive | 28 | 34 | 1 | 3 |
| Stable persistently positive | 21 | 29 | 2 | 2 |
| Newly treatment-induced positive | 38 | 41 | 2 | 2 |
| ADA treatment boosted positive | 6 | 6 | 0 | 1 |
| Decreased in titre | 17 | 9 | 2 | 1 |
| Only post-baseline positive | 48 | 48 | 2 | 1 |
| ADA incidence | 44 | 47 | 2 | 3 |
| Transiently Positive | 22 | 26 | 1 | 3 |
| Only baseline positive | 9 | 4 | 0 | 0 |
| nAb positive | 57 | 75 | 3 | 4 |
Assessments for the presence of ADA and nAb throughout study
| Participants | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|
| Positive at any visit | 1 | 5 |
| Base- and Post-baseline Positive | 0 | 3 |
| Newly Persistently Positive | 0 | 2 |
| Stable persistently positive | 0 | 3 |
| Newly treatment-induced positive | 1 | 1 |
| ADA treatment boosted positive | 0 | 2 |
| Decreased in titre | 0 | 2 |
| Only post-baseline positive | 1 | 2 |
| ADA incidence | 1 | 3 |
| Transiently Positive | 1 | 0 |
| Only baseline positive | 0 | 0 |
| nAb positive | 1 | 5 |
Collected over Adults completed 56 weeks of treatment period and 12 weeks follow-up period; and adolescents completed 108 weeks of treatment period and 12 weeks follow-up period.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 5/783 (0.6%) | 102/783 (13%) | 415/783 (53%) |
| SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 4/793 (0.5%) | 94/793 (11.9%) | 409/793 (51.6%) |
| ZONDA - Benralizumab 30 mg q.4 Weeks | 0/49 (0%) | 10/49 (20.4%) | 33/49 (67.3%) |
| ZONDA - Benralizumab 30 mg q.8 Weeks | 1/49 (2%) | 9/49 (18.4%) | 38/49 (77.6%) |
| Event | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 36/783 | 26/793 | 3/49 | 2/49 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/783 | 0/793 | 1/49 | 0/49 |
| Acute myocardial infarctionCardiac disorders | 1/783 | 2/793 | 1/49 | 0/49 |
| Inguinal herniaGastrointestinal disorders | 0/783 | 1/793 | 0/49 | 1/49 |
| PneumoniaInfections and infestations | 2/783 | 4/793 | 0/49 | 1/49 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/783 | 0/793 | 0/49 | 1/49 |
| Colitis ulcerativeGastrointestinal disorders | 0/783 | 0/793 | 0/49 | 1/49 |
| GastritisGastrointestinal disorders | 2/783 | 0/793 | 1/49 | 0/49 |
| DiverticulitisInfections and infestations | 0/783 | 0/793 | 1/49 | 0/49 |
| Lower respiratory tract infectionInfections and infestations | 0/783 | 0/793 | 0/49 | 1/49 |
| Event | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 124/783 | 130/793 | 14/49 | 13/49 |
| BronchitisInfections and infestations | 50/783 | 51/793 | 3/49 | 10/49 |
| Upper respiratory tract infectionInfections and infestations | 61/783 | 56/793 | 0/49 | 7/49 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 62/783 | 53/793 | 4/49 | 7/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/783 | 20/793 | 5/49 | 0/49 |
| Oedema peripheralGeneral disorders | 4/783 | 6/793 | 0/49 | 4/49 |
| SinusitisInfections and infestations | 22/783 | 18/793 | 3/49 | 4/49 |
| Back painMusculoskeletal and connective tissue disorders | 24/783 | 21/793 | 2/49 | 4/49 |
| HeadacheNervous system disorders | 38/783 | 40/793 | 2/49 | 4/49 |
| Influenza like illnessGeneral disorders | 27/783 | 30/793 | 3/49 | 1/49 |
Full analysis population defined as treated for at least 1 treatment, excluding patients enrolled in MELTEMI.
| Age, Continuous(Years) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks | Total |
|---|---|---|---|---|---|
| Mean | 51.1 ± 13.79 | 48.9 ± 15.53 | 49.7 ± 10.35 | 52.7 ± 8.90 | 50.1 ± 14.48 |
| Sex: Female, Male(Participants) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks | Total |
|---|---|---|---|---|---|
| Female | 503 | 470 | 27 | 29 | 1029 |
| Male | 280 | 323 | 22 | 20 | 645 |
| Race/Ethnicity, Customized(Participants) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | ZONDA - Benralizumab 30 mg q.4 Weeks | ZONDA - Benralizumab 30 mg q.8 Weeks | Total |
|---|---|---|---|---|---|
| White | 599 | 612 | 45 | 42 | 1298 |
| Black and African American | 16 | 19 | 0 | 1 | 36 |
| Asian | 138 | 136 | 4 | 6 | 284 |
| Other | 30 | 26 | 0 | 0 | 56 |
Showing the first 100 of 431 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Oct 2017, 34 months.
Results were first posted in Feb 2019, 1 year 3 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 34 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab